Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLExpression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML, Published online: 30 January 2018; doi:10.1038/leu.2017.348Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML

Source: Leukemia - January 30, 2018 Category: Hematology Authors: C Sch ütz S Inselmann S Saussele C T Dietz M C M üller E Eigendorff C A Brendel S K Metzelder T H Br ümmendorf C Waller J Dengler M E Goebeler R Herbst G Freunek S Hanzel T Illmer Y Wang T Lange F Finkernagel R Hehlmann M Huber A Neubauer A Hochhaus J Source Type: research